jbt-101
Small moleculeexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02466243)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jbt-101
- jbt-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03093402 | Phase 2 | Aug 1, 2017 | Feinstein Institute for Medical Research, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02465450 | Phase 2 | Sep 1, 2015 | Case Western Reserve University, Corbus Pharmaceuticals Inc., Queen's University, Belfast |
| NCT02465437 | Phase 2 | Aug 1, 2015 | Corbus Pharmaceuticals Inc., Cornell University |
| NCT02466243 | Phase 2 | Jun 1, 2015 | Corbus Pharmaceuticals Inc., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Pennsylvania |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Inc. | For profit | 3 | 3 | 1 | 2015 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Feinstein Institute for Medical Research | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2017 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2015 |
| Queen's University, Belfast | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2015 |
8 organizations
Page 1 / 1